Seeking Alpha

Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial

An objective response rate of 48.2% was observed with ifinatamab deruxtecan in these previously treated patients Discussions with global regulatory authorities underway SCLC is aggressive and ...
MedPage Today on MSN

High Response Rates in Platinum-Resistant Ovarian Cancer With Immunotherapy Agents

Also from SGO: p53 reactivator active in advanced gynecologic cancers, "perfect" score in ...
Nasdaq

Iovance Biotherapeutics Reports 61% Response Rate for Amtagvi® in Third-Line Melanoma Patients

Iovance Biotherapeutics announced promising results from a real-world study of its commercially available Amtagvi® (lifileucel) for treating advanced melanoma in patients previously treated with ...
Seeking Alpha

TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today ...